Taking Stock of Radius Health’s Financial Performance
Of this revenue, $3.4 million came from product revenue, which comprises Tymlos sales and licensing revenue. For 2017 and 2018, Radius Health is expected to post revenue of $23 million and $97.7 million, respectively. Array Biopharma (ARRY) is expected to report revenue of $108 million in 2018.